PriceTargets.com logo

NewAmsterdam Pharma - NAMS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.33
  • Forecasted Upside: 92.08%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$22.56 As of 03/26/2025 05:00 PM ET
▼ -0.85 (-3.63%)

This chart shows the closing price for NAMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$22.56Closing price on 03/26/25:
Get New NewAmsterdam Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NAMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NAMS

Analyst Price Target is $43.33
▲ +92.08% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for NewAmsterdam Pharma in the last 3 months. The average price target is $43.33, with a high forecast of $52.00 and a low forecast of $37.00. The average price target represents a 92.08% upside from the last price of $22.56.

This chart shows the closing price for NAMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$11$21$31$42$52Closing price on 03/26/25: $22.56High$52.00Average$43.33Low$37.00




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in NewAmsterdam Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2025

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/3/2025UBS GroupSet Target$41.00
2/27/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.00
2/27/2025Needham & Company LLCLower TargetBuy ➝ Buy$46.00 ➝ $42.00
1/24/2025Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
1/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$48.00 ➝ $48.00
12/30/2024HC WainwrightInitiated CoverageBuy$48.00
12/11/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$35.00 ➝ $47.00
12/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
11/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
9/23/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$37.00 ➝ $37.00
9/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
8/28/2024Needham & Company LLCInitiated CoverageBuy$36.00
7/30/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
6/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
5/15/2024TD CowenInitiated CoverageBuy
3/14/2024ScotiabankInitiated CoverageSector Outperform ➝ Sector Outperform$35.00
2/29/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$25.00 ➝ $31.00
1/18/2024GuggenheimInitiated CoverageBuy$30.00
1/16/2024Piper SandlerInitiated CoverageOverweight$37.00
11/22/2023William BlairReiterated RatingOutperform
10/30/2023Royal Bank of CanadaInitiated CoverageOutperform$25.00
4/3/2023Credit Suisse GroupBoost TargetOutperform$21.00 ➝ $22.00
1/6/2023Credit Suisse GroupInitiated CoverageOutperform$21.00
12/20/2022Leerink PartnersInitiated CoverageOutperform$19.00
12/19/2022William BlairInitiated CoverageOutperform
12/19/2022Jefferies Financial GroupInitiated CoverageBuy$24.00
(Data available from 3/27/2020 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2024
  • 15 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2024
  • 29 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2024
  • 11 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2025
  • 10 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2025
  • 13 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2025

Current Sentiment

  • 13 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More

Today's Range

Now: $22.56
Low: $22.05
High: $23.34

50 Day Range

MA: $21.72
Low: $17.53
High: $24.07

52 Week Range

Now: $22.56
Low: $15.19
High: $27.29

Volume

1,113,645 shs

Average Volume

519,365 shs

Market Capitalization

$2.48 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NewAmsterdam Pharma?

The following sell-side analysts have issued research reports on NewAmsterdam Pharma in the last twelve months: HC Wainwright, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Scotiabank, TD Cowen, and UBS Group AG.
View the latest analyst ratings for NAMS.

What is the current price target for NewAmsterdam Pharma?

0 Wall Street analysts have set twelve-month price targets for NewAmsterdam Pharma in the last year. Their average twelve-month price target is $43.33, suggesting a possible upside of 92.1%. Scotiabank has the highest price target set, predicting NAMS will reach $52.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $37.00 for NewAmsterdam Pharma in the next year.
View the latest price targets for NAMS.

What is the current consensus analyst rating for NewAmsterdam Pharma?

NewAmsterdam Pharma currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NAMS will outperform the market and that investors should add to their positions of NewAmsterdam Pharma.
View the latest ratings for NAMS.

What other companies compete with NewAmsterdam Pharma?

Other companies that are similar to NewAmsterdam Pharma include Ascendis Pharma A/S, Vaxcyte, Qiagen, Roivant Sciences and Sarepta Therapeutics. Learn More about companies similar to NewAmsterdam Pharma.

How do I contact NewAmsterdam Pharma's investor relations team?

NewAmsterdam Pharma's physical mailing address is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. The company's listed phone number is 352062971 and its investor relations email address is max.nowicki@frazierhealthcare.com. The official website for NewAmsterdam Pharma is www.newamsterdampharma.com. Learn More about contacing NewAmsterdam Pharma investor relations.





Receive NewAmsterdam Pharma News & Ratings Daily
Sign up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with PriceTargets.com’s free daily newsletter.